Capsules
BPC-157 Capsules
500 mcg × 100 capsules · capsule form
$180.00 CAD
BPC-157 capsules supplied for research-use catalogue ordering.
- CAS number
- 137525-51-0
- Current lot #
For laboratory and research use only - not for human consumption.
Latest lab results
Latest lab results
Checking the live COA archive for the newest lot documentation.
Previous lab results
Trace every archived lot result.
Use the verification archive to select a peptide name and review all published lot records alphabetically.
View previous lab resultsAbout this compound
This capsule listing uses the same BPC-157 research information as the vial listing, with capsule-specific quantity and order details.
What it has been researched for
Almost all BPC-157 research is preclinical, focused on gastrointestinal protection, soft-tissue research, angiogenesis, and cytoprotection models.
How it is thought to work
Leading hypotheses include angiogenesis-related signalling and nitric-oxide pathway interactions in laboratory models.
Regulatory status
BPC-157 is not an approved medicine in any jurisdiction, and this product is supplied as a research compound only. In July 2026 a US FDA advisory committee voted 8-6-1 to recommend BPC-157 for the American 503A compounding list, having reviewed it for one use only - ulcerative colitis - and against the recommendation of the FDA's own scientific reviewers. That vote is advisory and not binding: it concerns what US compounding pharmacies may work with, it is not a drug approval, and it takes effect only if the FDA accepts it and completes formal rulemaking. BPC-157 is also prohibited in sport at all times under the WADA Prohibited List, where it has been listed since January 2022 under category S0.
Product details
One capsule container with 100 capsules at 500 mcg per capsule.